Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02794571 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
A Phase 1 study of Advanced/Metastatic Tumors, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 518
- Enrollment target
- 20
- Study locations
NCT02794571: Completed Phase 1 study of Advanced/Metastatic Tumors, sponsored by Genentech.
NCT02794571 is a Phase 1 study of Advanced/Metastatic Tumors that has completed, run by Genentech. The registered enrollment target is 518 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (763% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02794571, a Phase 1 study of Advanced/Metastatic Tumors, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 518 participants
- Enrollment target
- 20
- Study locations
Study Summary
This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incurable tumors for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate, or for whom a clinical trial of an investigational agent is a recognized standard of care.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Tiragolumab
Study Locations (20)
Other
- Institut Bergonie CLCC Bordeaux - Bordeaux
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes - Lyon
- Institut Curie - Paris
- Institut Claudius Regaud; Departement Oncologie Medicale - Toulouse
- Institut Gustave Roussy - Villejuif
- National Cancer Center Hospital - Tokyo
- The Cancer Institute Hospital of Japanese Foundation For Cancer Research - Tokyo
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University Health System - Seoul
Arizona
- Honor Health Research Institute - Scottsdale
California
- University of California Los Angeles - Santa Monica
Connecticut
- Yale Cancer Center - New Haven
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Henry Ford Hospital - Detroit
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 1 |
What the finished NCT02794571 record still lists
NCT02794571 is an interventional study that assigns participants to a tested intervention. The registered 518 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (763% higher).
The record links to 1 condition, with Advanced/Metastatic Tumors appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT02794571 names 20 study sites across 12 states, led by Other, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT02794571 about?
NCT02794571 is a clinical study titled "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors". This first-in-human open-label, multicenter, dose-escalation and expansion study is designed to evaluate the safety, tolerability, and PK of tiragolumab alone or in combination with atezolizumab and/or other anti-cancer therapies in participants with locally advanced, recurrent, or metastatic incura...
What is the current status of trial NCT02794571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2016-05-23. Estimated completion is 2024-11-13.
What conditions does trial NCT02794571 study?
This clinical trial studies the following conditions: Advanced/Metastatic Tumors.
What interventions are being tested in trial NCT02794571?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT02794571?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02794571 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02794571's enrollment target sits among peer trials
518 40th of 2000 higher than 1,960 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI